国家税务总局关于外国投资者再投资退税有关问题的通知

上一篇: 国家工商行政管理局印发《关于改进企业登记管理工作，促进改革开放和经济发展的若干意见》的通知
下一篇: 劳动部、煤炭工业部、农业部、地质矿产部、监察部、全国总工会关于加强乡镇煤矿安全工作的通知

海南省三亚市人民政府


三亚市人民政府关于印发《三亚市国有单位土地资产处置管理办法》的通知

三府〔2012〕189号



各镇人民政府,各区管委会,市政府直属各单位：
《三亚市国有单位土地资产处置管理办法》已经六届市政府第8次常务会议审议通过，现印发给你们，请认真组织实施。





三亚市人民政府
2012年9月29日



三亚市国有单位土地资产处置管理办法


第一条 为加强我市国有单位土地资产管理，规范国有单位土地资产处置行为，防止国有资产流失，根据《中华人民共和国土地管理法》、《中华人民共和国企业国有资产法》、《中华人民共和国城镇国有土地使用权出让和转让暂行条例》、《海南经济特区土地管理条例》和《海南省国有企业改革划拨土地使用权管理办法》等有关规定, 结合我市实际，制定本办法。
第二条 本办法所指国有单位包括以下三类：
第一类是指党的机关、人大机关、行政机关、政协机关、审判机关、检察机关、民主党派机关，以及参照公务员管理的社会团体及其它承担行政职能、公益服务的市属事业单位（以下统称为“机关单位”）。
第二类是指自收自支的从事生产经营活动的市属事业单位（以下统称为“自收自支事业单位”）。
第三类是指由市人民政府代表国家履行出资人职责的国有独资企业、国有独资公司及其全资下属企业（以下统称为“企业”）。
第三条 本市国有单位土地资产处置行为适用本办法。
第四条 本办法所称土地资产，是指国有单位拥有土地使用权的土地（含划拨土地）及其附着物（含地下建筑物）。
土地资产处置，是指单位对拥有的土地资产部分或者全部转让给自然人、法人或者其他组织，或以股权转让（仅限企业）、土地使用权作价入股、合资合作等方式导致土地权属发生变化的行为（或其他土地实际控制权发生变化的情形）。
第五条 土地资产处置应符合城市规划要求，不得随意变更规划确定的用地性质和规划指标。
第六条 机关单位的划拨土地资产，不得有转让、抵押、作价入股、联营、合作开发、赠与、交换等处置行为。
经市财政部门审核，并经市政府批准，机关单位的划拨土地使用权可以进行临时出租，但累计出租年限不得超过两年。
第七条 机关单位在不影响正常工作的前提下，对本单位闲置的各类用房，经主管部门审核同意并经市财政部门审批后，可对外出租，如有两个以上意向承租人的应通过公开竞价的方式确定承租人。
机关单位房屋租赁收益管理按照《三亚市行政事业单位国有资产收益收缴管理暂行办法》的规定执行。
第八条 机关单位划拨土地，不得以补缴地价款的方式变为出让地。确有必要变为出让地的，由市人民政府收回后统一出让。但是，划拨土地上原有政策性住房依法转让涉及相应分摊土地补办出让手续的除外。
第九条 自收自支事业单位的划拨土地资产，符合法定条件的，经市人民政府批准，可以依法处置。
第十条 自收自支事业单位拟处置划拨土地资产,应当按以下程序审批：
(一)申报单位提出土地资产处置申请,上报主管部门。提交申请的资料包括:
1.土地资产处置书面申请;
2.土地资产处置申报表;
3.土地证、房产证及其他资产权属证明文件;
4.国有资产产权登记证;
5.价格评估报告（申报单位应当委托具有相应土地资产估价资格的机构对拟处置的土地资产进行价格评估）；
6.其他需要提交的文件、证件及资料。
(二)主管部门审核并签署意见后,报市财政部门。
(三)市财政部门根据有关规定进行调查论证,提出处置意见上报市人民政府。
(四)市人民政府分管领导组织论证，经市政府专题会议通过后，报市人民政府常务会议审定。
第十一条 经市人民政府批准对自收自支事业单位划拨土地资产进行处置的，按照以下程序办理：
(一)申报单位将土地价格评估结果报市国土部门备案和审核。评估报告经核准后，作为确定土地资产处置的参考依据。
(二)申报单位根据经核准的土地价格评估，提出土地资产处置方案，经市财政部门审核后报市人民政府审定实施。
第十二条 企业拟处置土地资产的，必须先提交处置申请，处置申请按以下程序审批：
（一）处置申请报市国资监管部门。申请内容包括：处置地块的基本情况（位置及四至范围、面积、权属、规划用途等）、价格评估报告（企业应当委托具有相应土地资产估价资格的机构对拟处置的土地资产进行价格评估）、土地处置目的、土地处置方式、土地处置后的用途、可行性分析、受让方（合作方）条件等。
（二）市国资监管部门根据有关规定对上报的申请进行审查，提出初步意见上报市人民政府。
（三）市人民政府分管领导组织论证，经市政府专题会议通过后，报市人民政府常务会议审定。
第十三条 经市人民政府批准对企业土地资产进行处置的，按以下程序办理：
（一）拟订处置方案。企业拟订土地资产处置方案，主要内容应当包括拟处置土地资产的状况、拟处置方式、职工安置方案、拟处置价格及理由、拟处置后土地用途及土地使用权年限等。
职工安置方案应当提交职工代表大会审议通过。
（二）评估结果备案和土地资产处置方案审核。企业将土地价格评估结果和土地资产处置方案报市国土部门备案和审核。由市国土部门对土地产权状况、地价水平进行初步审查，出具意见, 并附土地估价结果初审表。
（三）处置方案审批。企业将经市国土部门审核的土地资产处置方案，报市国资监管部门审查。市国资监管部门根据有关规定对上报的资料进行审查，提出处置意见上报市人民政府审批。
（四）办理国有资本金转增手续。经市人民政府批准，以作价出资（入股）方式处置土地资产的，由企业持处置批准文件到市国资监管部门办理国有资本金转增手续。
（五）签订合同与变更土地房屋登记。土地资产处置方案经批准后，采取出让方式处置的，受让人应当持处置批准文件和其他有关文件与市国土部门签订土地出让合同，补交土地使用权出让金，并按照规定办理土地房屋变更登记手续；采取以土地资产作价出资（入股）方式处置的，企业应当持市人民政府处置批准文件和转增资本金批准文件（或转增资本金证明）以及土地变更登记所要求的其他材料，到市国土部门，按照规定办理土地房屋变更登记手续。
第十四条 涉及土地资产交易的，除符合国家有关规定可协议处置外，均应严格按照有关程序公开操作，并在国有土地交易市场或省国有资产监督管理机构认可的产权交易机构进行公开交易。
以联营、合作开发方式处置土地资产的，联营、合作开发的对象应当通过公开竞争方式选择。
第十五条 企业关闭、破产的，划拨土地使用权及地上附着物由市人民政府依法处置。
处置收入按照“收支两条线”的方式管理，全额缴入财政专户。同时按照“以收定支、收支平衡”的原则，通过财政预算安排支出，由市国资监管部门统筹优先用于安置关闭、破产企业职工。
第十六条 国有单位有下列情形之一者，由市国土部门报原批准机关批准，收回划拨土地使用权：
（一）用地单位已经撤销或者迁移的；
（二）未经原批准机关同意，连续2年未使用土地的；
（三）不按批准的用途使用土地的；
（四）因迁移、解散、撤销、破产或者其他原因而停止使用土地的；
（五）市人民政府根据城市建设发展需要和城市规划的要求。
第十七条 对未经依法批准登记擅自出让、转让、租赁、抵押土地使用权的，根据《海南经济特区土地管理条例》第七十五条的规定，市国土部门应当没收其违法所得，可以并处违法所得20%以上50％以下罚款。
第十八条 未经批准，擅自处置土地资产或对外签订与土地资产处置有关的合资合作开发等合同的，对直接负责的主管人员和其他直接责任人员，依法给予行政处分；构成犯罪的，依法追究刑事责任。
第十九条 经办单位和监督检查人员滥用职权，徇私舞弊、玩忽职守，不认真履行工作和监督检查职责，造成国有资产损失的，视情节轻重，给予相应的行政处分，构成犯罪的，依法追究刑事责任。
第二十条 市人民政府代表国家履行出资人职责的国有资本控股公司及其下属控股企业，在三亚的中央、省属企业使用的划拨土地，国家有特别规定的，按相关规定办理，国家没有特别规定的，参照本办法执行。
第二十一条 本办法由市人民政府负责解释。
第二十二条 本办法自公布之日起施行。本办法施行前已经市政府批准的土地资产处置项目，按原批准方案执行。




Commissioner of SFDA


Provisions for Drug Insert Sheets and Labels



(SFDA Decree No.24)

The Provisions for Drug Insert Sheets and Labels, adopted at the executive meeting of the State Food and Drug Administration on March 10, 2006, is hereby promulgated and shall go into effect as of June 1, 2006.


Shao Mingli
Commissioner of SFDA

March 15, 2006





Provisions for Drug Insert Sheets and Labels


Chapter I General Provisions

Article 1 The Provisions are enacted with a view to regulating drug insert sheets and labels in accordance with the Drug Administration Law of the People’s Republic of China and the Regulations for Implementation of the Drug Administration Law of the People’s Republic of China.

Article 2 The insert sheets and labels of drugs marketed within the territory of the People’s Republic of China shall meet the requirements of the Provisions.

Article 3 Drug insert sheets and labels shall be reviewed and approved by the State Food and Drug Administration.

A drug shall be labeled on the basis of its insert sheet. The content of the label shall be within the scope of the insert sheet. Any words and marks with implied therapeutic effects, misleading information on usage, or inappropriate promotion of the product shall not be printed.

Article 4 A drug label shall be printed on or affixed to the drug package, and no other written words, audio and/or visual materials or other information are attached to introduce or publicize the product or the enterprise.

An insert sheet shall be attached to the smallest package provided by the drug manufacturer for marketing.

Article 5 The wording in drug insert sheets and labels shall be scientific, standardized and accurate. The insert sheet of a non-prescription drug shall be written intelligibly and convenient for patients to judge, choose and use the drug on their own.

Article 6 In the label or insert sheet, the letters or characters shall be clear and easy to be recognized and the marks shall be clear and distinctive. The label and insert sheet shall have no print faded and shall not be affixed unsteadily. Any addition or modification shall not be made by means of pasting, cutting or altering.

Article 7 Drug insert sheets and labels shall be written in standardized Chinese characters published by the National Language Commission. The versions in other languages shall comply with the Chinese version.

Article 8 With the aim to protect public health and direct the rational use of drugs, drug manufacturers may voluntarily apply to add warnings to drug insert sheets or labels. The State Food and Drug Administration may also request drug manufacturers to add warnings to drug insert sheets or labels.


Chapter II Drug Insert Sheet

Article 9 A drug insert sheet shall include the significant scientific data, conclusions and information concerning drug safety and efficacy in order to direct the safe and rational use of drugs. The specific format, content and writing requirements of drug insert sheet shall be prescribed and issued by the State Food and Drug Administration.

Article 10 Disease names, pharmaceutical terms, drug names, the names and results of clinical testing in drug insert sheets shall be expressed in professional terms published or standardized by the State. The units of measurement shall conform to the national standards.

Article 11 All the active ingredients or medicinal ingredients of traditional Chinese medicines in a prescription shall be listed in the insert sheet. For injections and non-prescription drugs, all excipients shall be listed as well.

The ingredients or excipients included in a prescription, which may cause severe adverse reaction, shall be specified.

Article 12 A drug manufacturer shall trace the safety and efficacy of its marketed drugs. For any modification to the insert sheet, an application shall be submitted timely.

The State Food and Drug Administration may also require a drug manufacturer to make modification to the insert sheet on the basis of the results of adverse drug reaction monitoring and drug re-evaluation.

Article 13 After the modification to the insert sheet is approved, the drug manufacturer shall inform relevant drug distributors, drug users and other departments of the modified content immediately, and use the modified insert sheet and label timely as required.

Article 14 The insert sheet shall provide full information on adverse drug reaction and indicate the adverse reactions in detail. A drug manufacturer, who fails to timely modify the insert sheet on the basis of the safety and efficacy data of the marketed drug or to fully explain the adverse reaction in the insert sheet, shall be liable for all the consequences arising therefrom.

Article 15 The approval date and the modification date shall be distinctively shown in the insert sheet.


Chapter III Drug Labels

Article 16 Drug labels refer to the information printed or pasted on drug packaging, including inner labels and outer labels. Inner labels refer to those that appear on immediate packaging; outer labels are those on the other packaging outside of inner labels.

Article 17 The inner label shall bear such drug information as the adopted name in China, indications or functions, strength, dose and usage, production date, batch number, expiry date and manufacturer. If there is no enough space in the package to include all the information mentioned above, the adopted name in China, strength, batch number and expiry date shall be indicated at least.

Article 18 The outer label of a drug shall indicate such information as the adopted name in China, ingredients, description, indications or functions, strength, dose and usage, adverse reactions, contraindications, precautions, storage, production date, batch number, expiry date, approval number and manufacturer. Where indications or functions, dose and usage, adverse reactions, contraindications and precautions cannot be fully noted, main information plus a “See drug insert sheet for details.” notice shall be indicated.

Article 19 The label on the package for transportation and storage shall bear at least the adopted name in China, strength, storage, production date, batch number, expiry date, approval number and manufacturer. Other information such as packaging quantity, precautions for transportation or other marks may be included when necessary.

Article 20 The label for drug substance shall include the adopted name in China, storage, production date, batch number, expiry date, applied specifications, approval number and manufacturer. Other necessary information such as packaging quantity and precautions for transportation shall also be indicated.

Article 21 Where one drug produced by a manufacturer has the same drug strength and packaging specification, the content, format and color of its labels must be the same. Where one drug produced by a manufacturer has different drug strengths or packaging specifications, its labels shall be clearly distinguished from one another, or its specifications shall be notably marked in the corresponding specification items.

Where a drug produced by a manufacturer is administrated as prescription drug and non-prescription drug respectively, their packaging colors shall be distinctly different.

Article 22 For drugs with special requirements on storage, its requirements shall be marked in the notable place of the label.

Article 23 The expiry date in the drug label shall appear in the order of year, month and day, with year shown in four digits, month and day in two digits. Its specific format shall be “Valid till XXXX year XX month” or “Valid till XXXX year XX month XX day”. It may be presented with numbers and other symbols as “Valid till XXXX.XX.” or “Valid till XXXX/XX/XX”.

For the preventive biological product, the expiry date shall be labeled according to the registration specifications approved by the State Food and Drug Administration. The expiry date of the biological product for therapeutic use shall be counted from the filling date. For other drugs, the expiry date shall be counted from the production date.

Where the expiry date is labeled to the day, it shall be marked as one day earlier than the actual expiry date; where the expiry date is labeled to the month, it shall be marked as one month earlier than the actual expiry month.


Chapter IV Use of Drug Name and Registered Trademark

Article 24 The drug name in insert sheets and labels shall conform to the nomenclature principles on the adopted name in China and trade name of drug announced by the State Food and Drug Administration, and shall be consistent with those appeared in the approval documents of the drug.

Article 25 The adopted name in China shall be conspicuous and prominent, and its typeface, size and color shall be consistent, and meet the following requirements:
(1) For horizontal labels, the adopted name in China shall appear in a prominent position within the area of the upper one-third of the label; for vertical labels, it shall appear in a prominent position within the area of the right one-third of the label;
(2) No such illegible typefaces as cursive characters and seal characters shall be used, and no such format as italics, margining and shading shall be used to modify the typefaces.
(3) The font color of the adopted name in China shall be black or white, in sharp contrast to the light-colored or dark-colored background respectively.
(4) Writing in separate lines shall be avoided unless limited by the packaging size.

Article 26 The trade name of a drug shall not be placed in the same line with the adopted name in China; its typeface and color shall be no more conspicuous than that of the adopted name in China, and its font area per character shall be no bigger than half of that of the adopted name in China.

Article 27 Unregistered trademarks and other drug names unapproved by the State Food and Drug Administration shall not be used in the drug insert sheets and labels.

Where a registered trademark is used in a drug label, it shall be printed in a corner of the label. Where a registered trademark contains characters, the font area per character shall be no bigger than a quarter of that of the adopted name in China.


Chapter V Other Provisions

Article 28 For narcotic drugs, psychotropic substances, medicinal toxic drugs, radioactive pharmaceuticals, drugs for topical use, non-prescription drugs and other drugs having special marks specified by the State, their special marks shall be printed in the drug insert sheets and labels.
Where there are special provisions issued by the State for drug insert sheets and labels, they shall prevail.

Article 29 The labeling provisions for Chinese crude drugs and prepared slices of Chinese crude drugs shall be formulated separately by the State Food and Drug Administration.

Article 30 Where drug insert sheets and labels are not in compliance with the Provisions, a punishment shall be imposed in accordance with the relevant provisions of the Drug Administration Law of the People’s Republic of China.


Chapter VI Supplementary Provisions

Article 31 These Provisions shall come into force as of June 1, 2006. the Provisions for Drug Packaging, Labels and Insert Sheets (Provisional) issued by State Food and Drug Administration on October 15, 2005 shall be annulled therefrom.